Neuroreceptor imaging in depression

Neurobiology of Disease

Volumn 52, Issue , 2013, Pages 49-65

  Savitz, Jonathan B ^a,b   Drevets, Wayne C ^a,c  

^a LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^b Tulsa School of Community Medicine   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Bipolar disorder; Cortisol; CRF; Depression; Dopamine; Gene; Major depressive disorder; Neuroimaging; Positron emission tomography; Postmortem; Receptor; Serotonin; Stress; Transporter

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BRAIN RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; MUSCARINIC M2 RECEPTOR; RADIOLIGAND; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

BIPOLAR DISORDER; BRAIN REGION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; ENDOCRINE DISEASE; HUMAN; INFLAMMATION; LIGAND BINDING; MAJOR DEPRESSION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; SEROTONINERGIC SYSTEM;

BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE; RECEPTOR, MUSCARINIC M2; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84873522293     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.001     Document Type: Review

References (200)

1. Albert P.R., Francois B.L. Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front. Neurosci. 2010, 4:35.
2. Albert P., Lu J., Lefrancois B., Burns A.M., Stockmeier C.A., Austin M.C., Overholser J.C., Jurjus G., Meltzer H. Increased DNA methylation of the 5-HT1A receptor promoter in suicide brain. Int. J. Neuropsychopharmacol. 2008, 11:105-106.
3. Allard P., Norlen M. Caudate nucleus dopamine D(2) receptors in depressed suicide victims. Neuropsychobiology 2001, 44:70-73.
4. Anand A., Barkay G., Dzemidzic M., Albrecht D., Karne H., Zheng Q.H., Hutchins G.D., Normandin M.D., Yoder K.K. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011, 13:406-413.
5. Anisman H., Du L., Palkovits M., Faludi G., Kovacs G.G., Szontagh-Kishazi P., Merali Z., Poulter M.O. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J. Psychiatry Neurosci. 2008, 33:131-141.
6. Arango V., Ernsberger P., Marzuk P.M., Chen J.S., Tierney H., Stanley M., Reis D.J., Mann J.J. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch. Gen. Psychiatry 1990, 47:1038-1047.
7. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 1995, 688:121-133.
8. Arango V., Underwood M.D., Boldrini M., Tamir H., Kassir S.A., Hsiung S., Chen J.J., Mann J.J. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001, 25:892-903.
9. Arranz B., Eriksson A., Mellerup E., Plenge P., Marcusson J. Brain 5-HT1A, 5-HT1D, and 5-HT2 receptors in suicide victims. Biol. Psychiatry 1994, 35:457-463.
10. Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann. N. Y. Acad. Sci. 1997, 836:158-181.
11. Attar-Levy D., Martinot J.L., Blin J., Dao-Castellana M.H., Crouzel C., Mazoyer B., Poirier M.F., Bourdel M.C., Aymard N., Syrota A., Feline A. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol. Psychiatry 1999, 45:180-186.
12. Bacher I., Houle S., Xu X., Zawertailo L., Soliman A., Wilson A.A., Selby P., George T.P., Sacher J., Miler L., Kish S.J., Rusjan P., Meyer J.H. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch. Gen. Psychiatry 2011, 68:817-826.
13. Barton D.A., Esler M.D., Dawood T., Lambert E.A., Haikerwal D., Brenchley C., Socratous F., Hastings J., Guo L., Wiesner G., Kaye D.M., Bayles R., Schlaich M.P., Lambert G.W. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch. Gen. Psychiatry 2008, 65:38-46.
14. Basso A.M., Gallagher K.B., Bratcher N.A., Brioni J.D., Moreland R.B., Hsieh G.C., Drescher K., Fox G.B., Decker M.W., Rueter L.E. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 2005, 30:1257-1268.
15. Baumann B., Bielau H., Krell D., Agelink M.W., Diekmann S., Wurthmann C., Trubner K., Bernstein H.G., Danos P., Bogerts B. Circumscribed numerical deficit of dorsal raphe neurons in mood disorders. Psychol. Med. 2002, 32:93-103.
16. Bhagwagar Z., Rabiner E.A., Sargent P.A., Grasby P.M., Cowen P.J. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry 2004, 9:386-392.
17. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am. J. Psychiatry 2006, 163:1580-1587.
18. Bhagwagar Z., Murthy N., Selvaraj S., Hinz R., Taylor M., Fancy S., Grasby P., Cowen P. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am. J. Psychiatry 2007, 164:1858-1865.
19. Biver F., Wikler D., Lotstra F., Damhaut P., Goldman S., Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br. J. Psychiatry 1997, 171:444-448.
20. Blakely R.D., Ramamoorthy S., Schroeter S., Qian Y., Apparsundaram S., Galli A., Defelice L.J. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry 1998, 44:169-178.
21. Blier P., Bouchard C. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br. J. Pharmacol. 1994, 113:485-495.
22. Blier P., de Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 1987, 7:24S-35S.
23. Blier P., Pineyro G., El Mansari M., Bergeron R., De Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. N. Y. Acad. Sci. 1998, 861:204-216.
24. Boldrini M., Underwood M.D., Mann J.J., Arango V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J. Psychiatr. Res. 2008, 42:433-442.
25. Boileau I., Warsh J.J., Guttman M., Saint-Cyr J.A., McCluskey T., Rusjan P., Houle S., Wilson A.A., Meyer J.H., Kish S.J. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov. Disord. 2008, 23(12):1776-1780.
26. Bowden C., Theodorou A.E., Cheetham S.C., Lowther S., Katona C.L., Crompton M.R., Horton R.W. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res. 1997, 752:227-233.
27. Bowen D.M., Najlerahim A., Procter A.W., Francis P.T., Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9504-9508.
28. Buck A., Gucker P.M., Schönbächler R.D., Arigoni M., Kneifel S., Vollenweider F.X., Ametamey S.M., Burger C. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. J. Cereb. Blood Flow Metab. 2000, 20(2):253-262.
29. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., Rollis D., Drevets M., Gandhi S., Solorio G., Drevets W.C. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 2006, 63:741-747.
30. Cannon D.M., Ichise M., Fromm S.J., Nugent A.C., Rollis D., Gandhi S.K., Klaver J.M., Charney D.S., Manji H.K., Drevets W.C. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol. Psychiatry 2006, 60:207-217.
31. Cannon D.M., Ichise M., Rollis D., Klaver J.M., Gandhi S.K., Charney D.S., Manji H.K., Drevets W.C. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol. Psychiatry 2007, 62:870-877.
32. Cannon D.M., Klaver J.M., Peck S.A., Rallis-Voak D., Erickson K., Drevets W.C. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology 2009, 34:1277-1287.
33. Cannon D.M., Klaver J.K., Gandhi S.K., Solorio G., Peck S.A., Erickson K., Akula N., Savitz J., Eckelman W.C., Furey M.L., Sahakian B.J., McMahon F.J., Drevets W.C. Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol. Psychiatry 2011, 16:407-418.
34. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130:226-238.
35. Carlson P., Bain E., Tinsley R., Nugent A., Carson R., Luckenbaugh D., Kling M., Gold P., Remaley A., Drevets W. Relationship between serotonin-1A binding and HPA axis in subjects with major depression and healthy controls. Neuroimage 2008, 41:T146.
36. Carr G.V., Lucki I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl) 2011, 213:265-287.
37. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
38. Christian B.T., Fox A.S., Oler J.A., Vandehey N.T., Murali D., Rogers J., Oakes T.R., Shelton S.E., Davidson R.J., Kalin N.H. Serotonin transporter binding and genotype in the nonhuman primate brain using [C-11]DASB PET. Neuroimage 2009, 47:1230-1236.
39. David S.P., Murthy N.V., Rabiner E.A., Munafo M.R., Johnstone E.C., Jacob R., Walton R.T., Grasby P.M. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J. Neurosci. 2005, 25:2586-2590.
40. Dougherty D.D., Bonab A.A., Ottowitz W.E., Livni E., Alpert N.M., Rauch S.L., Fava M., Fischman A.J. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress. Anxiety 2006, 23:175-177.
41. Drevets W.C., Furey M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 2010, 67:432-438.
42. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., Huang Y., Gautier C., Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1999, 46:1375-1387.
43. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Greer P.J., Mathis C. Serotonin type-1A receptor imaging in depression. Nucl. Med. Biol. 2000, 27:499-507.
44. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., Mathis C. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 2007, 34:865-877.
45. Ekuni D., Firth J.D., Nayer T., Tomofuji T., Sanbe T., Irie K., Yamamoto T., Oka T., Liu Z., Vielkind J., Putnins E.E. Lipopolysaccharide-induced epithelial monoamine oxidase mediates alveolar bone loss in a rat chronic wound model. Am. J. Pathol. 2009, 175:1398-1409.
46. Erritzoe D., Frokjaer V.G., Haugbol S., Marner L., Svarer C., Holst K., Baare W.F., Rasmussen P.M., Madsen J., Paulson O.B., Knudsen G.M. Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage 2009, 46:23-30.
47. Erritzoe D., Frokjaer V.G., Haahr M.T., Kalbitzer J., Svarer C., Holst K.K., Hansen D.L., Jernigan T.L., Lehel S., Knudsen G.M. Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage 2010, 52:284-289.
48. Fernandes C., McKittrick C.R., File S.E., McEwen B.S. Decreased 5-HT1A and increased 5-HT2A receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety. Psychoneuroendocrinology 1997, 22:477-491.
49. Fisher P.M., Meltzer C.C., Ziolko S.K., Price J.C., Moses-Kolko E.L., Berga S.L., Hariri A.R. Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. Nat. Neurosci. 2006, 9:1362-1363.
50. Fisher P.M., Meltzer C.C., Price J.C., Coleman R.L., Ziolko S.K., Becker C., Moses-Kolko E.L., Berga S.L., Hariri A.R. Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling. Cereb. Cortex 2009, 19:2499-2507.
51. Fisher P.M., Price J.C., Meltzer C.C., Moses-Kolko E.L., Becker C., Berga S.L., Hariri A.R. Medial prefrontal cortex serotonin 1A and 2A receptor binding interacts to predict threat-related amygdala reactivity. Biol. Mood Anxiety Disord. 2011, 1:2.
52. Frokjaer V.G., Mortensen E.L., Nielsen F.A., Haugbol S., Pinborg L.H., Adams K.H., Svarer C., Hasselbalch S.G., Holm S., Paulson O.B., Knudsen G.M. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol. Psychiatry 2008, 63:569-576.
53. Frokjaer V.G., Vinberg M., Erritzoe D., Svarer C., Baare W., Budtz-Joergensen E., Madsen K., Madsen J., Kessing L.V., Knudsen G.M. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 2009, 46(2):360-366.
54. Frokjaer V.G., Vinberg M., Erritzoe D., Baare W., Holst K.K., Mortensen E.L., Arfan H., Madsen J., Jernigan T.L., Kessing L.V., Knudsen G.M. Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology 2010, 35:1129-1137.
55. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 2006, 63:1121-1129.
56. Gordon I., Weizman R., Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur. J. Pharmacol. 1996, 298:27-30.
57. Gray L., Scarr E., Dean B. Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res. 2006, 143:111-120.
58. Grecksch G., Zhou D., Franke C., Schroder U., Sabel B., Becker A., Huether G. Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex: behavioural correlates. Br. J. Pharmacol. 1997, 122:1725-1731.
59. Gross C., Zhuang X., Stark K., Ramboz S., Oosting R., Kirby L., Santarelli L., Beck S., Hen R. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002, 416:396-400.
60. Gunther L., Liebscher S., Jahkel M., Oehler J. Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice. Eur. J. Pharmacol. 2008, 593:49-61.
61. Gunther L., Rothe J., Rex A., Voigt J.P., Millan M.J., Fink H., Bert B. 5-HT(1A)-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test. Neuropharmacology 2011, 61:433-441.
62. Hammoud D.A., Endres C.J., Hammond E., Uzuner O., Brown A., Nath A., Kaplin A.I., Pomper M.G. Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV. Neuroimage 2010, 49:2588-2595.
63. Hasbi A., Fan T., Alijaniaram M., Nguyen T., Perreault M.L., O'Dowd B.F., George S.R. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21377-21382.
64. Hasler G., Bonwetsch R., Giovacchini G., Toczek M.T., Bagic A., Luckenbaugh D.A., Drevets W.C., Theodore W.H. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol. Psychiatry 2007, 62(11):1258-1264.
65. Heinz A., Higley J.D., Gorey J.G., Saunders R.C., Jones D.W., Hommer D., Zajicek K., Suomi S.J., Lesch K.P., Weinberger D.R., Linnoila M. In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am. J. Psychiatry 1998, 155:1023-1028.
66. Hirvonen J., Karlsson H., Kajander J., Lepola A., Markkula J., Rasi-Hakala H., Nagren K., Salminen J.K., Hietala J. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int. J. Neuropsychopharmacol. 2008, 11:465-476.
67. Hirvonen J., Karlsson H., Kajander J., Markkula J., Rasi-Hakala H., Nagren K., Salminen J.K., Hietala J. Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl) 2008, 197:581-590.
68. Homberg J.R., Lesch K.P. Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 2011, 69:513-519.
69. Horikawa H., Kato T.A., Mizoguchi Y., Monji A., Seki Y., Ohkuri T., Gotoh L., Yonaha M., Ueda T., Hashioka S., Kanba S. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:1306-1316.
70. Hrdina P.D., Demeter E., Vu T.B., Sotonyi P., Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res. 1993, 614:37-44.
71. Ichimiya T., Suhara T., Sudo Y., Okubo Y., Nakayama K., Nankai M., Inoue M., Yasuno F., Takano A., Maeda J., Shibuya H. Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol. Psychiatry 2002, 51:715-722.
72. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
73. Ishihara K., Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn. J. Pharmacol. 1999, 80:185-189.
74. Johnson S., Stockmeier C.A., Meyer J.H., Austin M.C., Albert P.R., Wang J., May W.L., Rajkowska G., Overholser J.C., Jurjus G., Dieter L., Johnson C., Sittman D.B., Ou X.M. The reduction of R1, a novel repressor protein for monoamine oxidase a, in major depressive disorder. Neuropsychopharmacology 2011, 36:2139-2148.
75. Jovanovic H., Perski A., Berglund H., Savic I. Chronic stress is linked to 5-HT(1A) receptor changes and functional disintegration of the limbic networks. Neuroimage 2011, 55:1178-1188.
76. Judge S.J., Ingram C.D., Gartside S.E. Moderate differences in circulating corticosterone alter receptor-mediated regulation of 5-hydroxytryptamine neuronal activity. J. Psychopharmacol. 2004, 18:475-483.
77. Kalbitzer J., Erritzoe D., Holst K.K., Nielsen F.A., Marner L., Lehel S., Arentzen T., Jernigan T.L., Knudsen G.M. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol. Psychiatry 2010, 67:1033-1039.
78. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 2011, 68:444-454.
79. Kavelaars A., Cobelens P.M., Teunis M.A., Heijnen C.J. Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene. J. Neuroimmunol. 2005, 161:162-168.
80. Keck M.E., Sartori S.B., Welt T., Muller M.B., Ohl F., Holsboer F., Landgraf R., Singewald N. Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment. J. Neurochem. 2005, 92:1170-1179.
81. Kestler L.P., Malhotra A.K., Finch C., Adler C., Breier A. The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO personality inventory-revised. Neuropsychiatry Neuropsychol. Behav. Neurol. 2000, 13:48-52.
82. Kienast T., Hariri A.R., Schlagenhauf F., Wrase J., Sterzer P., Buchholz H.G., Smolka M.N., Grunder G., Cumming P., Kumakura Y., Bartenstein P., Dolan R.J., Heinz A. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat. Neurosci. 2008, 11:1381-1382.
83. Kim J.H., Son Y.D., Kim H.K., Lee S.Y., Cho S.E., Kim Y.B., Cho Z.H. Association of harm avoidance with dopamine D2/3 receptor availability in striatal subdivisions: a high resolution PET study. Biol. Psychol. 2011, 87:164-167.
84. Klimek V., Schenck J.E., Han H., Stockmeier C.A., Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 2002, 52:740-748.
85. Kobiella A., Vollstadt-Klein S., Buhler M., Graf C., Buchholz H.G., Bernow N., Yakushev I.Y., Landvogt C., Schreckenberger M., Grunder G., Bartenstein P., Fehr C., Smolka M.N. Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli. Hum. Brain Mapp. 2010, 31:716-726.
86. Kuroda Y., Mikuni M., Ogawa T., Takahashi K. Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors. Psychopharmacology (Berl) 1992, 108:27-32.
87. Lai Y.T., Tsai Y.P., Cherng C.G., Ke J.J., Ho M.C., Tsai C.W., Yu L. Lipopolysaccharide mitagates methamphetamine-induced striatal dopamine depletion via modulating local TNF-alpha and dopamine transporter expression. J. Neural Transm. 2009, 116:405-415.
88. Landau A.M., Chakravarty M.M., Clark C.M., Zis A.P., Doudet D.J. Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 2011, 36:511-518.
89. Laruelle M., Vanisberg M.A., Maloteaux J.M. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol. Psychiatry 1988, 24:299-309.
90. Law A.J., Pei Q., Walker M., Gordon-Andrews H., Weickert C.S., Feldon J., Pryce C.R., Harrison P.J. Early parental deprivation in the Marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder. Neuropsychopharmacology 2008, 34(6):1381-1394.
91. Lee T.T., Redila V.A., Hill M.N., Gorzalka B.B. 5-HT(2A) receptor mediated neuronal activation within the paraventricular nucleus of the hypothalamus is desensitized following prolonged glucocorticoid treatment. Eur. J. Pharmacol. 2009, 602:54-57.
92. Lemonde S., Turecki G., Bakish D., DU L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003, 23:8788-8799.
93. Lin A., Song C., Kenis G., Bosmans E., de Jongh R., Scharpe S., Maes M. The in vitro immunosuppressive effects of moclobemide in healthy volunteers. J. Affect. Disord. 2000, 58:69-74.
94. Lin Y.L., Lin S.Y., Wang S. Prenatal lipopolysaccharide exposure increases anxiety-like behaviors and enhances stress-induced corticosterone responses in adult rats. Brain Behav. Immun. 2012, 26:459-468.
95. Links J.M., Zubieta J.K., Meltzer C.C., Stumpf M.J., Frost J.J. Influence of spatially heterogeneous background activity on "hot object" quantitation in brain emission computed tomography. J. Comput. Assist. Tomogr. 1996, 20:680-687.
96. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for neurobiology of depression. Biol. Psychiatry 1998, 43:547-573.
97. Lopez-Figueroa A.L., Norton C.S., Lopez-Figueroa M.O., Armellini-Dodel D., Burke S., Akil H., Lopez J.F., Watson S.J. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 2004, 55:225-233.
98. Lucas L.R., Celen Z., Tamashiro K.L., Blanchard R.J., Blanchard D.C., Markham C., Sakai R.R., McEwen B.S. Repeated exposure to social stress has long-term effects on indirect markers of dopaminergic activity in brain regions associated with motivated behavior. Neuroscience 2004, 124:449-457.
99. Magalhaes A.C., Holmes K.D., Dale L.B., Comps-Agrar L., Lee D., Yadav P.N., Drysdale L., Poulter M.O., Roth B.L., Pin J.P., Anisman H., Ferguson S.S. CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat. Neurosci. 2010, 13:622-629.
100. Mann J.J., Currier D. A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch. Suicide Res. 2007, 11:3-16.
101. Mazziotta J.C., Phelps M.E., Plummer D., Kuhl D.E. Quantitation in positron emission computed tomography: 5. Physical-anatomical effects. J. Comput. Assist. Tomogr. 1981, 5:734-743.
102. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., Mulsant B.H., Ben-Eliezer D., Lopresti B., Dekosky S.T., Reynolds C.F. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 1999, 156:1871-1878.
103. Meltzer C.C., Price J.C., Mathis C.A., Butters M.A., Ziolko S.K., Moses-Kolko E., Mazumdar S., Mulsant B.H., Houck P.R., Lopresti B.J., Weissfeld L.A., Reynolds C.F. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 2004, 29:2258-2265.
104. Messa C., Colombo C., Moresco R.M., Gobbo C., Galli L., Lucignani G., Gilardi M.C., Rizzo G., Smeraldi E., Zanardi R., Artigas F., Fazio F. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) 2003, 167:72-78.
105. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 2007, 32(2):86-102.
106. Meyer J.H., Kapur S., Houle S., Dasilva J., Owczarek B., Brown G.M., Wilson A.A., Kennedy S.H. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am. J. Psychiatry 1999, 156:1029-1034.
107. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., Dasilva J., Wilson A.A., Rafi-Tari S., Mayberg H.S., Kennedy S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am. J. Psychiatry 2001, 158:78-85.
108. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., Minifie C., Houle S., Hussey D., Kennedy S.H. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001, 12:4121-4125.
109. Meyer J.H., McMain S., Kennedy S.H., Korman L., Brown G.M., Dasilva J.N., Wilson A.A., Blak T., Eynan-Harvey R., Goulding V.S., Houle S., Links P. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am. J. Psychiatry 2003, 160:90-99.
110. Meyer J.H., Houle S., Sagrati S., Carella A., Hussey D.F., Ginovart N., Goulding V., Kennedy J., Wilson A.A. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry 2004, 61:1271-1279.
111. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., Young T., Praschak-Rieder N., Wilson A.A., Houle S. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006, 63:1209-1216.
112. Meyer J.H., McNeely H.E., Sagrati S., Boovariwala A., Martin K., Verhoeff N.P., Wilson A.A., Houle S. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am. J. Psychiatry 2006, 163:1594-1602.
113. Meyer J.H., Wilson A.A., Sagrati S., Miler L., Rusjan P., Bloomfield P.M., Clark M., Sacher J., Voineskos A.N., Houle S. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 2009, 66:1304-1312.
114. Mickey B.J., Ducci F., Hodgkinson C.A., Langenecker S.A., Goldman D., Zubieta J.K. Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J. Neurosci. 2008, 28:11354-11359.
115. Miller A.H., Pariante C.M., Pearce B.D. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv. Exp. Med. Biol. 1999, 461:107-116.
116. Miller J.M., Oquendo M.A., Ogden R.T., Mann J.J., Parsey R.V. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J. Psychiatr. Res. 2008, 42:1137-1144.
117. Miller J.M., Brennan K.G., Ogden T.R., Oquendo M.A., Sullivan G.M., Mann J.J., Parsey R.V. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 2009, 34:2275-2284.
118. Miller J.M., Kinnally E.L., Ogden R.T., Oquendo M.A., Mann J.J., Parsey R.V. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse 2009, 63:565-573.
119. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 1984, 15:217-227.
120. Mintun M.A., Sheline Y.I., Moerlein S.M., Vlassenko A.G., Huang Y., Snyder A.Z. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol. Psychiatry 2004, 55:217-224.
121. Montgomery A.J., Stokes P., Kitamura Y., Grasby P.M. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J. Affect. Disord. 2007, 101:113-122.
122. Moresco F.M., Dieci M., Vita A., Messa C., Gobbo C., Galli L., Rizzo G., Panzacchi A., de Peri L., Invernizzi G., Fazio F. In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study. Neuroimage 2002, 17:1470-1478.
123. Moron J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., Lin Z.C., Wang J.B., Javitch J.A., Galli A., Shippenberg T.S. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 2003, 23:8480-8488.
124. Moses-Kolko E.L., Wisner K.L., Price J.C., Berga S.L., Drevets W.C., Hanusa B.H., Loucks T.L., Meltzer C.C. Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil. Steril. 2008, 89:685-692.
125. Murrough J.W., Henry S., Hu J., Gallezot J.D., Planeta-Wilson B., Neumaier J.F., Neumeister A. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl) 2011, 213:547-553.
126. Murthy N.V., Selvaraj S., Cowen P.J., Bhagwagar Z., Riedel W.J., Peers P., Kennedy J.L., Sahakian B.J., Laruelle M.A., Rabiner E.A., Grasby P.M. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 2010, 52:50-54.
127. Oler J.A., Fox A.S., Shelton S.E., Christian B.T., Murali D., Oakes T.R., Davidson R.J., Kalin N.H. Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. J. Neurosci. 2009, 29:9961-9966.
128. Oquendo M.A., Hastings R.S., Huang Y.Y., Simpson N., Ogden R.T., Hu X.Z., Goldman D., Arango V., van Heertum R.L., Mann J.J., Parsey R.V. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch. Gen. Psychiatry 2007, 64:201-208.
129. Ordway G.A., Farley J.T., Dilley G.E., Overholser J.C., Meltzer H.Y., Balraj E.K., Stockmeier C.A., Klimek V. Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res. 1999, 847:71-79.
130. Pandey G.N., Dwivedi Y., Rizavi H.S., Ren X., Pandey S.C., Pesold C., Roberts R.C., Conley R.R., Tamminga C.A. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am. J. Psychiatry 2002, 159:419-429.
131. Pantazopoulos H., Stone D., Walsh J., Benes F.M. Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 2004, 54:147-155.
132. Parsey R.V., Hastings R.S., Oquendo M.A., Hu X., Goldman D., Huang Y.Y., Simpson N., Arcement J., Huang Y., Ogden R.T., van Heertum R.L., Arango V., Mann J.J. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am. J. Psychiatry 2006, 163:48-51.
133. Parsey R.V., Hastings R.S., Oquendo M.A., Huang Y.Y., Simpson N., Arcement J., Huang Y., Ogden R.T., van Heertum R.L., Arango V., Mann J.J. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am. J. Psychiatry 2006, 163:52-58.
134. Parsey R.V., Ogden R.T., Miller J.M., Tin A., Hesselgrave N., Goldstein E., Mikhno A., Milak M., Zanderigo F., Sullivan G.M., Oquendo M.A., Mann J.J. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol. Psychiatry 2010, 68:170-178.
135. Pearlson G.D., Wong D.F., Tune L.E., Ross C.A., Chase G.A., Links J.M., Dannals R.F., Wilson A.A., Ravert H.T., Wagner H.N., et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch. Gen. Psychiatry 1995, 52:471-477.
136. Pei L., Li S., Wang M., Diwan M., Anisman H., Fletcher P.J., Nobrega J.N., Liu F. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat. Med. 2010, 16:1393-1395.
137. Pineda E.A., Hensler J.G., Sankar R., Shin D., Burke T.F., Mazarati A.M. Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression. Neuropsychopharmacology 2011, 36:1305-1316.
138. Politis M., Wu K., Loane C., Turkheimer F.E., Molloy S., Brooks D.J., Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-1927.
139. Praschak-Rieder N., Kennedy J., Wilson A.A., Hussey D., Boovariwala A., Willeit M., Ginovart N., Tharmalingam S., Masellis M., Houle S., Meyer J.H. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol. Psychiatry 2007, 62:327-331.
140. Praschak-Rieder N., Willeit M., Wilson A.A., Houle S., Meyer J.H. Seasonal variation in human brain serotonin transporter binding. Arch. Gen. Psychiatry 2008, 65:1072-1078.
141. Rahmim A., Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl. Med. Commun. 2008, 29:193-207.
142. Reimold M., Smolka M.N., Schumann G., Zimmer A., Wrase J., Mann K., Hu X.Z., Goldman D., Reischl G., Solbach C., Machulla H.J., Bares R., Heinz A. Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J. Neural Transm. 2007, 114:635-639.
143. Reimold M., Batra A., Knobel A., Smolka M.N., Zimmer A., Mann K., Solbach C., Reischl G., Schwarzler F., Grunder G., Machulla H.J., Bares R., Heinz A. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol. Psychiatry 2008, 13(606-13):557.
144. Reimold M., Knobel A., Rapp M.A., Batra A., Wiedemann K., Strohle A., Zimmer A., Schonknecht P., Smolka M.N., Weinberger D.R., Goldman D., Machulla H.J., Bares R., Heinz A. Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl) 2011, 213:563-572.
145. Reivich M., Amsterdam J.D., Brunswick D.J., Shiue C.Y. PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression. J. Affect. Disord. 2004, 82:321-327.
146. Rhodes R.A., Murthy N.V., Dresner M.A., Selvaraj S., Stavrakakis N., Babar S., Cowen P.J., Grasby P.M. Human 5-HT transporter availability predicts amygdala reactivity in vivo. J. Neurosci. 2007, 27:9233-9237.
147. Richardson-Jones J.W., Craige C.P., Guiard B., Metzger K.L., Dranovsky A., David D., Gardier A.M., Beck S.G., Hen R., Leonardo E. Dissociating the Roles of the 5-HT1A Auto- and Heteroreceptors in Depression and Anxiety: Insights from a Novel Genetic Mouse System 2009, Society for Neuroscience, Chicago.
148. Rossi D.V., Valdez M., Gould G.G., Hensler J.G. Chronic administration of venlafaxine fails to attenuate 5-HT1A receptor function at the level of receptor-G protein interaction. Int. J. Neuropsychopharmacol. 2006, 9:393-406.
149. Sacher J., Wilson A.A., Houle S., Rusjan P., Hassan S., Bloomfield P.M., Stewart D.E., Meyer J.H. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch. Gen. Psychiatry 2010, 67:468-474.
150. Sadzot B., Lemaire C., Maquet P., Salmon E., Plenevaux A., Degueldre C., Hermanne J.P., Guillaume M., Cantineau R., Comar D., et al. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J. Cereb. Blood Flow Metab. 1995, 15:787-797.
151. Saijo T., Takano A., Suhara T., Arakawa R., Okumura M., Ichimiya T., Ito H., Okubo Y. Electroconvulsive therapy decreases dopamine D receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [(1)(1)C]FLB 457. J. Clin. Psychiatry 2010, 71:793-799.
152. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 2004, 14:1100-1109.
153. Sargent P.A., Kjaer K.H., Bench C.J., Rabiner E.A., Messa C., Meyer J., Gunn R.N., Grasby P.M., Cowen P.J. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 2000, 57:174-180.
154. Sargent P.A., Rabiner E.A., Bhagwagar Z., Clark L., Cowen P., Goodwin G.M., Grasby P.M. 5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635. J. Affect. Disord. 2010, 123:77-80.
155. Savitz J.B., Drevets W.C. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009, 164:300-330.
156. Savitz J., Lucki I., Drevets W.C. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 2009, 88:17-31.
157. Scheggi S., Marchese G., Grappi S., Secci M.E., de Montis M.G., Gambarana C. Cocaine sensitization models an anhedonia-like condition in rats. Int. J. Neuropsychopharmacol. 2011, 14:333-346.
158. Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav. Brain Funct. 2010, 6:24.
159. Selvaraj S., Murthy N.V., Bhagwagar Z., Bose S.K., Hinz R., Grasby P.M., Cowen P.J. Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl) 2011, 213:555-562.
160. Sesack S.R., Grace A.A. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010, 35:27-47.
161. Shelton R.C., Sanders-Bush E., Manier D.H., Lewis D.A. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009, 158:1406-1415.
162. Shively C.A., Friedman D.P., Gage H.D., Bounds M.C., Brown-Proctor C., Blair J.B., Henderson J.A., Smith M.A., Buchheimer N. Behavioral depression and positron emission tomography-determined serotonin 1A receptor binding potential in cynomolgus monkeys. Arch. Gen. Psychiatry 2006, 63:396-403.
163. Shrestha S., Hirvonen J., Hines C.S., Henter I.D., Svenningsson P., Pike V.W., Innis R.B. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage 2012, 59:3243-3251.
164. Sibille E., Lewis D.A. SERT-ainly involved in depression, but when?. Am. J. Psychiatry 2006, 163:8-11.
165. Slotkin T.A., Seidler F.J., Ritchie J.C. Effects of aging and glucocorticoid treatment on monoamine oxidase subtypes in rat cerebral cortex: therapeutic implications. Brain Res. Bull. 1998, 47:345-348.
166. Smiley J.F., Goldman-Rakic P.S. Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique. Cereb. Cortex 1993, 3:223-238.
167. Soliman A., Bagby R.M., Wilson A.A., Miler L., Clark M., Rusjan P., Sacher J., Houle S., Meyer J.H. Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. Psychol. Med. 2011, 41:1051-1060.
168. Soloff P.H., Price J.C., Mason N.S., Becker C., Meltzer C.C. Gender, personality, and serotonin-2A receptor binding in healthy subjects. Psychiatry Res. 2010, 181:77-84.
169. Stanley M., Mann J.J. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983, 1:214-216.
170. Stockmeier C.A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 2003, 37:357-373.
171. Stockmeier C.A., Shapiro L.A., Dilley G.E., Kolli T.N., Friedman L., Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J. Neurosci. 1998, 18:7394-7401.
172. Suhara T., Nakayama K., Inoue O., Fukuda H., Shimizu M., Mori A., Tateno Y. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl) 1992, 106:14-18.
173. Sullivan G.M., Ogden R.T., Oquendo M.A., Kumar J.S., Simpson N., Huang Y.Y., Mann J.J., Parsey R.V. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol. Psychiatry 2009, 66:223-230.
174. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007, 30:228-235.
175. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., Vaugeois J.M., Nomikos G.G., Greengard P. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006, 311:77-80.
176. Syvalahti E., Penttila J., Majasuo H., Palvimaki E.P., Laakso A., Hietala J. Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain. Pharmacopsychiatry 2006, 39:1-8.
177. Szabo S.T., Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001, 25:845-857.
178. Szewczyk B., Albert P.R., Burns A.M., Czesak M., Overholser J.C., Jurjus G.J., Meltzer H.Y., Konick L.C., Dieter L., Herbst N., May W., Rajkowska G., Stockmeier C.A., Austin M.C. Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. Int. J. Neuropsychopharmacol. 2008, 1-14.
179. Takahashi H., Takano H., Kodaka F., Arakawa R., Yamada M., Otsuka T., Hirano Y., Kikyo H., Okubo Y., Kato M., Obata T., Ito H., Suhara T. Contribution of dopamine D1 and D2 receptors to amygdala activity in human. J. Neurosci. 2010, 30:3043-3047.
180. Takano A., Arakawa R., Hayashi M., Takahashi H., Ito H., Suhara T. Relationship between neuroticism personality trait and serotonin transporter binding. Biol. Psychiatry 2007, 62:588-592.
181. Thalmeier A., Dickmann M., Giegling I., Schneider B., A.M.H., Maurer K., Schnabel A., Kauert G., Moller H.J., Rujescu D. Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. Int. J. Neuropsychopharmacol. 2008, 11:217-228.
182. Theodore W.H., Hasler G., Giovacchini G., Kelley K., Reeves-Tyer P., Herscovitch P., Drevets W. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007, 48:1526-1530.
183. Theodore W.H., Wiggs E.A., Martinez A.R., Dustin I.H., Khan O.I., Appel S., Reeves-Tyer P., Sato S. Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. Epilepsia 2012, 53:129-133.
184. Trajkovska V., Kirkegaard L., Krey G., Marcussen A.B., Thomsen M.S., Chourbaji S., Brandwein C., Ridder S., Halldin C., Gass P., Knudsen G.M., Aznar S. Activation of glucocorticoid receptors increases 5-HT2A receptor levels. Exp. Neurol. 2009, 218:83-91.
185. Turecki G., Briere R., Dewar K., Antonetti T., Lesage A.D., Seguin M., Chawky N., Vanier C., Alda M., Joober R., Benkelfat C., Rouleau G.A. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 1999, 156:1456-1458.
186. Underwood M.D., Mann J.J., Huang Y.Y., Arango V. Family history of alcoholism is associated with lower 5-HT2A receptor binding in the prefrontal cortex. Alcohol. Clin. Exp. Res. 2008, 32:593-599.
187. Underwood M.D., Kassir S.A., Bakalian M.J., Galfalvy H., Mann J.J., Arango V. Neuron density and serotonin receptor binding in prefrontal cortex in suicide. Int. J. Neuropsychopharmacol. 2011, 1-13.
188. van den Hove D., Jakob S.B., Schraut K.G., Kenis G., Schmitt A.G., Kneitz S., Scholz C.J., Wiescholleck V., Ortega G., Prickaerts J., Steinbusch H., Lesch K.P. Differential effects of prenatal stress in 5-htt deficient mice: towards molecular mechanisms of gene×environment interactions. PLoS One 2011, 6:e22715.
189. Wang S., Yan J.Y., Lo Y.K., Carvey P.M., Ling Z. Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Res. 2009, 1265:196-204.
190. Weisstaub N.V., Zhou M., Lira A., Lambe E., Gonzalez-Maeso J., Hornung J.P., Sibille E., Underwood M., Itohara S., Dauer W.T., Ansorge M.S., Morelli E., Mann J.J., Toth M., Aghajanian G., Sealfon S.C., Hen R., Gingrich J.A. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006, 313:536-540.
191. Willeit M., Praschak-Rieder N. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: a review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage 2010, 53:878-892.
192. Wong D.F., Pearlson G.D., Tune L.E., Young L.T., Meltzer C.C., Dannals R.F., Ravert H.T., Reith J., Kuhar M.J., Gjedde A. Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J. Cereb. Blood Flow Metab. 1997, 17:331-342.
193. Xiang L., Szebeni K., Szebeni A., Klimek V., Stockmeier C.A., Karolewicz B., Kalbfleisch J., Ordway G.A. Dopamine receptor gene expression in human amygdaloid nuclei: elevated D4 receptor mRNA in major depression. Brain Res. 2008, 1207:214-224.
194. Yamauchi M., Miyara T., Matsushima T., Imanishi T. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res. 2006, 1067:164-169.
195. Yatham L.N., Liddle P.F., Shiah I.S., Scarrow G., Lam R.W., Adam M.J., Zis A.P., Ruth T.J. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch. Gen. Psychiatry 2000, 57:850-858.
196. Yatham L.N., Liddle P.F., Lam R.W., Shiah I.S., Lane C., Stoessl A.J., Sossi V., Ruth T.J. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am. J. Psychiatry 2002, 159:1718-1723.
197. Zhang Y., Damjanoska K.J., Carrasco G.A., Dudas B., D'Souza D.N., Tetzlaff J., Garcia F., Hanley N.R., Scripathirathan K., Petersen B.R., Gray T.S., Battaglia G., Muma N.A., van de Kar L.D. Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J. Neurosci. 2002, 22:9635-9642.
198. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
199. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35:2510-2520.
200. Zhu X., Peng S., Zhang S., Zhang X. Stress-induced depressive behaviors are correlated with Par-4 and DRD2 expression in rat striatum. Behav. Brain Res. 2011, 223:329-335.